Marshall Gerstein Partner David A. Gass to Lead Panel on the IP Challenges of Commercializing Microbiome Research at 2017 BIO International Convention

Marshall Gerstein partner David A. Gass will lead a discussion on the IP challenges faced by those in the burgeoning field of microbiome research at the upcoming 2017 BIO International Convention. (Photo: Business Wire)

???pagination.previous??? ???pagination.next???

CHICAGO--()--Marshall, Gerstein & Borun LLP partner David A. Gass will lead a discussion at the upcoming 2017 BIO International Convention focused on the IP challenges faced by those in the burgeoning field of microbiome research into the commensal, symbiotic, and pathogenic microorganisms that share our body space and impact human health and disease.

Titled “Innovation and the Human Microbiome: Patent Eligibility and IP Protection,” the session will examine how laws and regulations in the U.S. and Europe, including recent U.S. Supreme Court decisions, affect patentability and other intellectual property rights. The panel will take place on June 20 from 1:45-2:45 p.m. in Room 1B of the San Diego Convention Center (111 W. Harbor Drive, San Diego, California).

“Even though microbiome research is identifying new avenues for diagnosis, therapy, and product development, IP challenges to commercialization still exist,” said Gass. “This session will look at those developments as well as how careful, thoughtful and creative approaches to patent drafting, trademark rights, and contractual provisions can be used to protect innovations in this area.”

In addition to Gass, who will serve as moderator, the session’s panelists include:

  • Michelle Booden, Senior Director, Technology Development; Director of Licensing and Intellectual Property, Salk Institute for Biological Studies
  • Amanda Barry, Associate General Counsel, Global Home Care & NA Fabric Care, The Procter & Gamble Company
  • Simon O’Brien, Partner & Patent Attorney, D Young & Co

The BIO International Convention is "the largest global event for the biotechnology industry," organized by the Biotechnology Innovation Organization (BIO), which represents biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. For more information about the conference, click here.

About Marshall, Gerstein & Borun LLP

Marshall, Gerstein & Borun LLP is exclusively focused on intellectual property law. The firm provides sophisticated intellectual property advice and legal services to many of the world’s largest, most innovative businesses, research institutions, universities, and entrepreneurs. Chambers & Partners has ranked Marshall, Gerstein as “first-rate for litigation,” and “one of the best biotechnology practices in the entire country.” Corporate Counsel magazine lists the Firm as a “Go-To Law Firm of the Top 500 Companies” for intellectual property and litigation. The Firm is also ranked as a top intellectual property law firm by Managing IP, Fortune, Intellectual Property Today, and Intellectual Asset Management magazines. Learn more at www.marshallip.com and www.PTABWatch.com.

Contacts

Marshall, Gerstein & Borun LLP
Anna Behrman, 312-474-6300

Release Summary

Marshall Gerstein partner David A. Gass will lead a discussion on the IP challenges faced by those in the burgeoning field of microbiome research at the upcoming 2017 BIO International Convention.

Contacts

Marshall, Gerstein & Borun LLP
Anna Behrman, 312-474-6300